相关实验视频

Updated: Jun 25, 2025

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

在炎症性肠病中,Helicobacter pylori和抗瘤缩因子α剂之间的免疫关系

Han Huang¹, Chenxiao Gan¹, Yan Cai^2,3,4

¹The Second School of Clinical Medicine, Zhejiang Chinese Medical University, China.

Central-European journal of immunology

|May 30, 2024

概括

杆菌可能会保护炎症性肠病 (IBD) 患者,可能与抗瘤坏死因子α (TNF-α) 疗法相互作用. 需要进一步的研究来理解这些复杂的机制.

科学领域:

胃肠病学胃肠病学
微生物学微生物学
免疫学免疫学免疫学

背景情况:

炎症性肠道疾病 (IBD) 涉及慢性肠道炎症,通常用抗瘤缩因子α (TNF-α) 等生物药物治疗.
胃肠杆菌Helicobacter pylori与炎症和胃癌有关.
新出现的证据表明,H. pylori在IBD患者中可能具有保护作用.

研究的目的:

审查H. pylori和抗TNF-α药物影响IBD发展和治疗的机制.
探索H. pylori感染和IBD中的抗TNF-α治疗之间的潜在相互作用.

主要方法:

对H. pylori,抗TNF-α药物和IBD的现有研究的文献综述.
对H. pylori在IBD中的作用提出的机制的综合.
分析H. pylori和抗TNF-α治疗之间的潜在相互作用.

主要成果:

杆菌感染对IBD病原和治疗的影响尚未完全理解.
抗TNF-α剂通过减少炎症对治疗IBD至关重要.
在IBD中,H. pylori和抗TNF-α剂之间的相互作用需要进一步研究.

结论:

了解H. pylori的作用可能为IBD提供新的治疗见解.
研究H. pylori和抗TNF-α剂之间的相互作用对于优化IBD管理至关重要.
进一步的研究对于阐明这些复杂的生物关系至关重要.

关键词:

在Helicobacter Pylori的研究中,的T淋巴细胞.抗瘤亡因子α的抗瘤药物.细胞因子细胞因子炎症性肠病是一种炎症性肠病.

更多相关视频

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability

High Resolution Electron Microscopy of the Helicobacter pylori Cag Type IV Secretion System Pili Produced in Varying Conditions of Iron Availability

Published on: November 21, 2014

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...